-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Cabaletta Bio, Raises Price Target to $16

Benzinga·03/24/2026 13:20:47
Listen to the news
Guggenheim analyst Yatin Suneja maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target from $15 to $16.